Evaluation of symptom burden in patients receiving concurrent biochemotherapy for metastatic malignant melanoma (MMM)

6143 Background: Combination of cytotoxic chemotherapy and immunoregulators (biochemotherapy) is commonly used to treat patients with MMM. Response rates reported with this regimen vary between 18%...